Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEPOLIZUMAB Cause Therapeutic product effect delayed? 10 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Therapeutic product effect delayed have been filed in association with MEPOLIZUMAB (Nucala). This represents 0.0% of all adverse event reports for MEPOLIZUMAB.

10
Reports of Therapeutic product effect delayed with MEPOLIZUMAB
0.0%
of all MEPOLIZUMAB reports
0
Deaths
4
Hospitalizations

How Dangerous Is Therapeutic product effect delayed From MEPOLIZUMAB?

Of the 10 reports, 4 (40.0%) required hospitalization.

Is Therapeutic product effect delayed Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does MEPOLIZUMAB Cause?

Asthma (11,033) Dyspnoea (9,192) Wheezing (6,093) Product dose omission issue (5,873) Cough (4,577) Pneumonia (4,107) Therapeutic product effect incomplete (4,106) Drug ineffective (3,880) Loss of personal independence in daily activities (3,566) Fatigue (2,656)

What Other Drugs Cause Therapeutic product effect delayed?

ADALIMUMAB (244) TOFACITINIB (178) CARBIDOPA\LEVODOPA (168) SECUKINUMAB (162) POLYETHYLENE GLYCOL 3350 (125) RIMEGEPANT (120) TASIMELTEON (93) DUPILUMAB (90) IBUPROFEN (88) DICLOFENAC (85)

Which MEPOLIZUMAB Alternatives Have Lower Therapeutic product effect delayed Risk?

MEPOLIZUMAB vs MEPROBAMATE MEPOLIZUMAB vs MERCAPTOPURINE MEPOLIZUMAB vs MEROPENEM MEPOLIZUMAB vs MEROPENEM ANHYDROUS MEPOLIZUMAB vs MESALAMINE

Related Pages

MEPOLIZUMAB Full Profile All Therapeutic product effect delayed Reports All Drugs Causing Therapeutic product effect delayed MEPOLIZUMAB Demographics